← Back

Pharvaris BV

Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with unmet needs, including angioedema and other bradykinin-mediated diseases. Its lead candidate, deucrictibant, is a small molecule bradykinin B2-receptor antagonist being developed to treat attacks caused by bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH). Deucrictibant is in phase 3 development for the treatment and prophylaxis of HAE attacks, and the company is also developing extended-release tablet and immediate-release capsule formulations. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Country
Price · split & dividend adjusted
News & notes moving PHVS
PHVS

Pharvaris Director Schikan Sold 37,600 Shares for $1.3 Million Under Trading Plan

Pharvaris N.V. Director Johannes Gerardus Christiaan Petrus Schikan sold 37,600 shares in open-market transactions valued at approximately $1.33 million, according to a SEC Form 4 filing. The sales occurred over June 29 and 30, 2026, at a weighted average price of around $35.41 per share, reducing his direct holdings by 10.66% to 315,167 shares. The transaction was executed under a Rule 10b5-1 trading plan and follows a 96.5% one-year share price gain as of June 30, 2026. Since March 2026, Schikan has completed four sell trades totaling 80,000 shares as part of a broader capacity-driven reduction. Pharvaris is a late-stage biotechnology company developing deucrictibant for hereditary angioedema, with the FDA recently accepting its New Drug Application for the on-demand treatment of attacks.
PHVS
The Motley Fool·56dRead more →
Biotech & Genomic Medicine▲

Pharvaris Announces Publication of Review Supporting Bradykinin B2 Receptor as Validated Target in Angioedema

Pharvaris announced the publication of a comprehensive review article in Clinical Reviews in Allergy & Immunology that summarizes decades of evidence supporting the bradykinin B2 receptor as a validated therapeutic target in bradykinin-mediated angioedema. The article provides a state-of-the-art overview of kinin biology and traces the evolution of bradykinin B2 receptor antagonism from foundational discoveries to a clinically validated approach. It highlights the established role of this mechanism in hereditary angioedema, including HAE with normal C1 inhibitor, and acquired angioedema due to C1 inhibitor deficiency, while also noting growing evidence that bradykinin signaling may contribute to a broader range of immunological and inflammatory disorders. Pharvaris is developing novel oral bradykinin B2 receptor antagonists, including deucrictibant, to address unmet needs in these conditions.
PHVS ▲
Biotech & Genomic Medicine ▲
GlobeNewswire·58dRead more →
Biotech & Genomic Medicine▲impact 4

Pharvaris says FDA accepts deucrictibant NDA for on-demand HAE attack treatment

Pharvaris announced that the U.S. Food and Drug Administration has accepted its New Drug Application for deucrictibant immediate-release capsule for the on-demand treatment of Hereditary Angioedema attacks. The FDA set a Prescription Drug User Fee Act target action date of April 23, 2027. The application includes data from over 1,300 treated HAE attacks, with clinical studies showing rapid onset of symptom relief and accelerated complete symptom resolution. The pivotal Phase 3 RAPIDe-3 study met its primary and all 11 secondary efficacy endpoints with statistical significance. Pharvaris stated it is poised for a successful launch if approved.
PHVS ▲
Biotech & Genomic Medicine
RTTNews·74dRead more →
© 2026 MarketDXAsset